ABSCI CORPORATION ABSI 深 沪
等待开盘 08-05 09:30:00 美东时间
2.99
+0.090
+3.10%
华盛通- 最 高3.01
- 今 开2.94
- 成交量 327.39万股
- 最 低 2.85
- 昨 收 2.90
- 总市值 4.31亿
- 52周最高 6.33
- 市盈率 静 --
- 换手率 2.27%
- 52周最低 2.01
- 委 比 -54.28%
- 总股本 1.44亿
- 历史最高 31.53
- 量 比 0.43
- 振 幅 5.52%
- 历史最低 1.1111
- 每 手 1
- 风险率 0.69%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Absci to Report Business Updates and Second Quarter 2025 Financial and Operating Results on August 12, 2025
Absci Corporation将于2025年8月12日收盘后公布2025年第二季度的业务更新及财务和运营结果。管理层将在美国东部时间下午4:30（太平洋时间下午1:30）举行电话会议讨论业务进展、财务结果和前景。投资者可以在公司投资者关系网站上收听直播，并在活动后观看重播。Absci致力于通过生成设计加速药物发现，其集成药物创建平台结合AI与合成生物学数据引擎，快速设计治疗难治性靶标的创新疗法。公司目前在研药物包括治疗炎症性肠病的ABS-101，以及治疗脱发的ABS-201。Absci总部位于华盛顿州温哥华，在纽约市和瑞士设有AI研究实验室和创新中心。
07-30 20:05
Morgan Stanley Maintains Overweight on Absci, Lowers Price Target to $6.4
Morgan Stanley analyst Vikram Purohit maintains Absci (NASDAQ:ABSI) with a Overweight and lowers the price target from $7 to $6.4.
07-28 20:54
Absci Launches $50M Public Stock Offering To Fund AI-Driven Drug Programs
Absci Corporation (NASDAQ:ABSI) ("Absci"), a clinical-stage biopharmaceutical company advancing potential breakthrough therapeutics designed with generative AI, announced today that it has commenced an underwritten
07-25 04:55
Absci Announces Pricing of Public Offering of Common Stock
Absci Corporation announced the pricing of an underwritten public offering of 16,670,000 shares of its common stock at $3.00 per share, with an option for underwriters to purchase up to an additional 2,500,500 shares. Proceeds of approximately $50 million will fund internal programs, platform investments, and general corporate purposes. Morgan Stanley, J.P. Morgan, Jefferies, and TD Cowen are joint book-running managers. The offering is registere...
07-25 00:45
Galaxy Digital, Blaize Holdings, Verizon And Other Big Stocks Moving Higher On Monday
U.S. stocks were higher, with the Dow Jones index gaining around 100 points on ...
07-21 22:16
Absci Appoints Biopharma Leader Mary Szela to Board of Directors
Absci announced the appointment of Mary Szela to its Board of Directors. With extensive experience in biopharmaceuticals, Szela led the global expansion of Humira® at Abbott. She joins Absci as it advances its AI-designed biologics, including ABS-101 for IBD and ABS-201 for androgenetic alopecia. Szela's tenure includes leadership roles at companies like Prometheus Biosciences and Novo Nordisk. Her expertise will support Absci's mission to innova...
07-07 12:00
Teleflex Catheters Cut ICU Infection Risk by Over 70%, Study Finds in 6-Country Trial
Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced findings from a new multinational study reporting efficacy of Arrow™ Chlorhexidine-Impregnated Central Venous
06-12 18:34
Needham Reiterates Buy on Absci, Maintains $9 Price Target
Needham analyst Gil Blum reiterates Absci (NASDAQ:ABSI) with a Buy and maintains $9 price target.
05-14 19:36
Why Everus Construction Group Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Shares of Everus Construction Group, Inc. (NYSE:ECG) rose sharply in today's pr...
05-14 17:20
